[HTML][HTML] COVID vaccine antibody responses in patients with hematologic malignancies in a myeloid enriched cohort: a better antibody response in patients with …
SY Goksu, J Rolwes, N Premnath, P Patel, R Ikpefan… - Blood, 2021 - Elsevier
Background: The risk of severe COVID-19 is increased in patients (pts) with hematologic
malignancies, with a reported risk of death of 34%(Vijenthira et al, 2020). The ASH-ASTCT …
malignancies, with a reported risk of death of 34%(Vijenthira et al, 2020). The ASH-ASTCT …
[HTML][HTML] COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with …
SY Goksu, J Rolwes, N Premnath, P Patel, R Ikpefan… - Blood, 2021 - ncbi.nlm.nih.gov
Background: The risk of severe COVID-19 is increased in patients (pts) with hematologic
malignancies, with a reported risk of death of 34%(Vijenthira et al, 2020). The ASH-ASTCT …
malignancies, with a reported risk of death of 34%(Vijenthira et al, 2020). The ASH-ASTCT …
[引用][C] COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with …
SY Goksu, J Rolwes, N Premnath, P Patel, R Ikpefan… - Blood, 2021 - experts.umn.edu
COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid
Enriched Cohort: A Better Antibody Response in Patients with Myeloid Malignancies Than …
Enriched Cohort: A Better Antibody Response in Patients with Myeloid Malignancies Than …
COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with Myeloid …
SY Goksu, J Rolwes, N Premnath, P Patel, R Ikpefan… - Blood, 2021 - ashpublications.org
Background: The risk of severe COVID-19 is increased in patients (pts) with hematologic
malignancies, with a reported risk of death of 34%(Vijenthira et al, 2020). The ASH-ASTCT …
malignancies, with a reported risk of death of 34%(Vijenthira et al, 2020). The ASH-ASTCT …
COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with Myeloid …
S Goksu, J Rolwes, N Premnath, P Patel, R Ikpefan… - Blood, 2021 - europepmc.org
Background: The risk of severe COVID-19 is increased in patients (pts) with hematologic
malignancies, with a reported risk of death of 34%(Vijenthira et al, 2020). The ASH-ASTCT …
malignancies, with a reported risk of death of 34%(Vijenthira et al, 2020). The ASH-ASTCT …
COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with Myeloid …
S Goksu, J Rolwes, N Premnath, P Patel, R Ikpefan… - Blood, 2021 - europepmc.org
Background: The risk of severe COVID-19 is increased in patients (pts) with hematologic
malignancies, with a reported risk of death of 34%(Vijenthira et al, 2020). The ASH-ASTCT …
malignancies, with a reported risk of death of 34%(Vijenthira et al, 2020). The ASH-ASTCT …